Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery

RecruitingOBSERVATIONAL
Enrollment

240

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2028

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Huaier granule

The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.

OTHER

Control

The subjects received standard platinum dual drug chemotherapy.The subjects were treated with carboplatin injection (300mg/m2, intravenous injection, first day) combined with pemetrexed disodium (pathological type: adenocarcinoma, intravenous injection, 500mg/m2) or albumin bound paclitaxel (pathological type: squamous cell carcinoma, 260mg/m2, intravenous injection, first day) every three weeks, with a maximum of four cycles.

Trial Locations (1)

110801

RECRUITING

Liaoning Cancer Hospital & Institute, Shenyang

All Listed Sponsors
collaborator

LinkDoc Technology (Beijing) Co. Ltd.

INDUSTRY

collaborator

Huazhong University of Science and Technology

OTHER

lead

Liaoning Cancer Hospital & Institute

OTHER

NCT06109454 - Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery | Biotech Hunter | Biotech Hunter